No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleonly females |
293218 |
2. Check conditionsNone |
293218 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
116 |
4. Check minimum number of eventsNone |
116 |
5. Include endpointsNone |
116 |
6. Filter based on genotype QC (FinnGen only) |
112 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of vagina, including Hilmo
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm, wide definition for exclusion
- Neoplasms
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 112 | 112 | - |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | - |
| Median age at first event (years) | 64.42 | 64.42 | - |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 116
- Matched controls
- 1160
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C52.91
ICD-10 Finland
Squamous cell carcinoma of the vagina
+∞
59.6
52
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
57.1
50
*
LEB00
NOMESCO Finland
Biopsy of vagina
102.9
49.6
52
9
A03FA01
ATC
metoclopramide; systemic, rectal
14.1
48.0
71
117
H02AB02
ATC
dexamethasone; systemic
107.1
44.0
46
7
XX3DW
NOMESCO Finland
Time consuming IT work
20.4
42.8
37
26
8070/3-C52.9
ICD-O-3
Squamous cell carcinoma, NOS, of vagina, NOS
+∞
42.3
38
*
ULA02
NOMESCO Finland
Kolposcopy
12.9
41.1
53
71
C52.90
ICD-10 Finland
Malignant neoplasm of vagina without histologic examination
+∞
37.6
34
*
WF002
NOMESCO Finland
Radical radiotherapy
165.1
34.9
35
*
A04AA01
ATC
ondansetron; systemic, rectal
49.9
33.7
40
12
JN4AD
NOMESCO Finland
Body CT examination
13.6
28.4
30
29
C52.99
ICD-10 Finland
Malignant tumor of the vagina, unspecified histology
+∞
28.3
26
*
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
8.6
28.1
49
91
C52
ICD-10 Finland
Malignant neoplasm of vagina
+∞
26.0
24
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
24.9
23
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
24.9
23
*
L03AA13
ATC
pegfilgrastim; parenteral
+∞
23.8
22
*
N02AA05
ATC
oxycodone; systemic
7.3
23.5
47
99
C52.92
ICD-10 Finland
Adenocarcinoma of the vagina
+∞
22.6
21
*
WZC00
NOMESCO Finland
Treatment plan or consultation
6.4
22.6
69
216
A04AA02
ATC
granisetron; systemic, transdermal
+∞
20.4
19
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
19.3
18
*
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
119.7
19.2
20
*
JN4BD
NOMESCO Finland
Extensive body CT
17.1
18.2
29
22
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
112.6
18.1
19
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
210.9
18.1
18
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
17.1
16
*
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
5.0
16.6
71
278
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.4
16.4
24
35
LX1XE
NOMESCO Finland
Other gynecological ultrasound examination
18.4
16.3
25
17
A04AD12
ATC
aprepitant; systemic
+∞
16.0
15
*
ZX040
NOMESCO Finland
Intracavity HDR radiotherapy
+∞
16.0
15
*
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
6.1
15.6
33
71
130
Kela drug reimbursment
Malignant tumour
+∞
14.9
14
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
14.9
14
*
Z51.5
ICD-10 Finland
Palliative care
15.6
14.7
24
19
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
19.4
14.1
21
13
B01AB10
ATC
tinzaparin; parenteral
6.3
13.9
27
53
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
+∞
13.8
13
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
13.8
13
*
L02BG04
ATC
letrozole; oral
36.7
13.0
16
5
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
78.7
12.9
14
*
YX9VG
NOMESCO Finland
Other MRI eamination with high intensity magnet for dose design of radiotherapy
+∞
12.7
12
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
12.7
12
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
12.7
12
*
PJA12
NOMESCO Finland
Sentinel node biopsy
145.0
12.7
13
*
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
14.0
12.4
21
18
UKC02
NOMESCO Finland
Cystoscopy
5.1
12.3
31
77
115
Kela drug reimbursment
Breast cancer
+∞
11.6
11
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
11.6
11
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
11.6
11
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
11.6
11
*
LEC00
NOMESCO Finland
Partial excision of vagina
+∞
11.6
11
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
11.6
11
*
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
6.2
11.6
22
42
TPX10
NOMESCO Finland
Implantation of vascular injection port
39.4
11.6
14
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
66.3
10.8
12
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
120.4
10.6
11
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
21.3
10.6
15
8
L03AA02
ATC
filgrastim; parenteral
+∞
10.6
10
*
YL1CD
NOMESCO Finland
Very extensive CT examination of pelvis for dose design of radiotherapy
+∞
10.6
10
*
X77
ICPC
Malignant neopl genital female other
+∞
10.6
10
*
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
+∞
10.6
10
*
WW500
NOMESCO Finland
Blood transfusion
22.5
10.1
14
7
WX302
NOMESCO Finland
Thoracal epidural anesthesy
19.7
9.7
14
8
LEB10
NOMESCO Finland
Excision of lesion of vagina
33.1
9.6
12
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
108.5
9.6
10
*
ZZR00
NOMESCO Finland
Flap of skin
108.5
9.6
10
*
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
9.5
9
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
9.5
9
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
9.5
9
*
WC105
NOMESCO Finland
Simple cytostatic therapy of local tumor recidive
+∞
9.5
9
*
N93.9
ICD-10 Finland
Abnormal uterine and vaginal bleeding, unspecified
18.1
8.8
13
8
D70.82
ICD-10 Finland
Drug-induced neutropenia
96.8
8.5
9
*
D39.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other female genital organs
96.8
8.5
9
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
8.4
8
*
A79
ICPC
Malignancy NOS
+∞
8.4
8
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
8.4
8
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
8.4
8
*
JN4CD
NOMESCO Finland
Very extensive body CT
20.0
7.8
11
6
ZX120
NOMESCO Finland
Intravenous
7.8
7.6
17
25
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
17.2
7.4
11
7
WC115
NOMESCO Finland
Cytostatic therapy of local tumor recidive with multiple drugs
+∞
7.4
7
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
7.4
7
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
7.4
7
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
7.4
7
*
LAF10
NOMESCO Finland
Bilateral salpingo-oophorectomy
7.9
7.3
16
23
WZC30
NOMESCO Finland
Teaching
4.0
7.3
23
67
R19.0
ICD-10 Finland
Intra-abdominal and pelvic swelling, mass and lump
11.1
7.2
13
13
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.0
7.0
22
64
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
3.8
6.5
22
67
J01EA01
ATC
trimethoprim; systemic
2.7
6.5
57
304
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
10.1
6.5
12
13
JN3AD
NOMESCO Finland
Abdominal CT examination
4.0
6.3
20
58
A06AH03
ATC
naloxegol; oral
28.4
6.3
8
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
6.3
6
*
C57.9
ICD-10 Finland
Malignant neoplasm: Female genital organ, unspecified
+∞
6.3
6
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
6.3
6
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
6.3
6
*
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
+∞
6.3
6
*
D07.1
ICD-10 Finland
Carcinoma in situ: Vulva
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
45
124
5.30
16.24
6.6
1.9
0.77
0.81
mmol/l
1.14
45
112
26
51
6.28
13.41
3.9
1.3
4.52
2.84
ug/l
0.64
19
41
79
450
3.37
8.73
16.9
12.5
1.35
1.26
inr
0.29
18
126
48
206
3.27
8.58
2.3
1.4
—
—
—
0
0
74
409
3.24
8.55
4.4
2.1
—
—
—
0
0
63
333
2.95
7.61
4.9
3.0
—
—
—
0
0
17
39
4.94
7.23
1.6
1.4
—
—
—
0
0
27
94
3.44
6.59
10.4
4.2
102.33
104.04
mmol/l
0.79
27
94
40
186
2.76
5.88
4.2
1.8
—
—
—
0
0
59
336
2.54
5.71
4.5
1.9
2.37
2.36
mmol/l
0.22
53
280
48
251
2.56
5.52
4.0
3.0
0.43
0.60
e6/l
0.43
41
175
31
130
2.89
5.48
2.5
1.8
—
—
—
0
0
24
95
2.92
4.66
2.5
1.8
—
—
—
0
0
24
97
2.86
4.49
2.4
1.8
—
—
—
0
0
28
127
2.59
4.19
12.0
6.7
—
—
—
0
0
12
27
4.83
4.07
1.2
1.2
104.83
67.61
pmol/l
0.66
12
27
7
7
10.54
4.06
1.6
1.1
—
—
—
0
0
7
7
10.54
4.06
1.6
1.1
—
—
—
0
0
11
23
5.17
3.98
1.3
1.2
—
—
—
0
0
8
13
6.52
3.56
1.6
1.3
—
—
—
0
0
6
6
10.45
3.54
1.7
1.2
—
—
—
0
0
6
6
10.45
3.54
1.7
1.2
—
—
—
0
0
24
110
2.49
3.49
4.3
2.2
21.69
22.80
%
0.13
17
95
44
263
2.08
3.42
6.4
4.1
0.00
0.00
estimate
—
10
82
8
14
6.05
3.40
1.5
1.3
—
—
—
0
0
16
60
2.93
3.39
2.5
1.4
—
—
—
0
0
21
92
2.57
3.34
9.9
2.3
5.32
5.81
kpa
1.75
21
92
11
29
4.08
3.28
3.5
1.4
2.89
1.50
ug/l
0.26
11
23
9
20
4.78
3.18
1.8
1.8
91.67
100.00
%
—
9
20
73
535
1.98
3.11
7.2
5.4
0.00
0.00
estimate
—
8
79
6
8
7.83
3.09
2.5
1.4
—
—
—
0
0
73
541
1.94
2.94
5.9
3.9
0.00
0.00
estimate
-0.00
11
81
6
9
6.96
2.90
1.8
1.3
—
—
—
0
0
68
494
1.91
2.89
9.7
4.6
1.20
1.23
mmol/l
2.27
60
441
62
440
1.88
2.81
9.7
4.3
1.20
1.23
mmol/l
1.83
57
399
12
40
3.23
2.79
10.3
2.6
23.79
24.94
mmol/l
0.67
12
40
8
19
4.44
2.73
2.6
1.4
—
—
—
0
0
30
169
2.05
2.66
3.9
2.5
1.04
1.39
e6/l
0.33
18
88
12
44
2.93
2.64
1.9
1.7
—
—
—
0
0
8
20
4.21
2.62
2.1
1.5
—
—
—
0
0
70
528
1.82
2.50
5.8
3.8
0.00
0.00
estimate
-0.00
11
89
5
8
6.47
2.39
1.0
1.0
—
—
—
0
0
15
66
2.46
2.36
1.7
1.6
43.17
59.86
ml/min/173m2
—
6
22
5
9
5.75
2.23
1.8
1.3
—
—
—
0
0
13
56
2.49
2.13
6.5
2.1
24.78
25.66
mmol/l
0.62
13
56
5
11
4.70
1.96
1.2
1.5
—
—
—
0
0
53
389
1.67
1.93
3.9
4.0
75.91
23.32
ng/l
0.45
42
279
6
17
3.66
1.86
1.2
1.1
—
—
—
0
0
5
12
4.30
1.84
1.0
1.1
—
—
—
0
0
18
97
2.01
1.78
12.0
2.5
1.02
1.04
mmol/l
0.08
18
80
6
18
3.46
1.77
1.7
1.3
—
—
—
0
0
6
18
3.46
1.77
1.7
1.3
—
—
—
0
0
93
1021
0.55
1.64
5.1
5.4
2.89
2.76
mmol/l
0.60
87
944
7
26
2.80
1.61
1.6
2.3
—
—
—
0
0
25
157
1.76
1.57
4.2
2.8
1.16
4.45
e6/l
2.06
13
78
92
1009
0.57
1.50
5.4
4.8
6.02
5.95
mmol/l
0.26
85
922
87
963
0.61
1.37
6.1
6.0
40.48
39.90
mmol/mol
0.21
79
893
5
17
3.02
1.37
1.4
1.1
—
—
—
0
0
14
76
1.96
1.37
4.1
1.2
64.71
67.54
g/l
0.47
14
70
34
244
1.56
1.28
2.6
2.0
3.09
3.44
mg/l
0.44
29
201
10
49
2.14
1.26
6.0
5.2
0.72
0.69
%
—
10
49
10
49
2.14
1.26
6.5
5.2
1.52
1.42
%
—
10
49
0
35
0.00
1.17
0.0
1.9
—
—
—
0
0
12
202
0.55
1.16
1.2
1.3
26.58
42.09
iu/ml
—
5
75
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
5
21
2.44
1.10
2.0
3.0
0.14
0.50
u/ml
—
5
12
10
52
2.01
1.10
7.1
2.0
0.60
0.67
%
—
10
52
10
52
2.01
1.10
2.3
1.4
—
—
—
0
0
12
197
0.56
1.06
1.3
1.3
3.26
11.42
u/ml
—
7
73
10
53
1.97
1.05
7.1
2.0
1.06
1.17
%
—
10
53
10
53
1.97
1.05
8.7
2.5
52.54
46.00
%
—
10
53
50
406
1.41
0.99
6.8
3.8
—
—
—
0
0
15
94
1.68
0.96
2.1
3.8
395.20
203.92
ng/l
0.33
15
85
29
215
1.47
0.93
1.7
1.7
1.30
1.03
mg/l
0.35
23
170
104
1089
0.57
0.93
46.9
18.0
123.41
132.53
g/l
7.62
104
1065
6
29
2.13
0.91
2.5
1.7
—
—
—
0
0
14
88
1.67
0.89
3.1
3.5
—
—
—
0
0
0
25
0.00
0.80
0.0
1.1
—
—
—
0
0
11
171
0.61
0.80
1.0
1.6
—
—
—
0
0
5
26
1.96
0.71
2.8
1.7
—
—
—
0
0
79
854
0.77
0.61
37.6
14.2
16.28
15.29
%
0.65
79
841
103
980
1.46
0.57
28.3
12.0
28.48
19.67
mg/l
2.12
93
720
48
418
1.25
0.52
4.1
2.6
179.94
82.83
ug/l
1.55
41
376
7
48
1.49
0.48
1.3
1.0
—
—
—
0
0
5
31
1.64
0.43
1.2
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
22.08
—
0
17
7
51
1.40
0.32
16.0
3.7
26.40
25.35
mmol/l
—
7
51
7
53
1.34
0.31
1.4
1.5
—
—
—
0
0
7
57
1.24
0.29
3.0
3.4
4.90
4.43
pmol/l
—
7
49
34
306
1.16
0.25
2.5
2.9
2172.00
1476.93
ng/l
0.28
29
262
5
42
1.20
0.22
1.4
1.2
—
—
—
0
0
5
42
1.20
0.22
1.4
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
4.02
—
0
6
0
13
0.00
0.21
0.0
2.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
72
752
0.89
0.20
3.4
4.5
16.11
12.53
mm/h
1.08
65
685
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
7
59
1.20
0.18
1.4
1.6
—
—
—
0
0
21
231
0.89
0.14
1.1
1.3
0.75
2.69
u/ml
—
8
53
95
930
1.12
0.13
22.7
11.0
73.61
76.05
ml/min/173m2
0.42
85
732
5
63
0.78
0.08
1.6
1.3
—
—
—
0
0
103
1041
0.91
0.06
31.9
14.4
138.76
139.89
mmol/l
3.30
103
1009
103
1041
0.91
0.06
31.9
14.4
3.98
3.96
mmol/l
0.26
103
1008
47
457
1.05
0.05
2.7
2.3
71.48
81.46
nmol/l
1.90
42
403
56
549
1.04
0.04
2.8
2.8
—
—
—
0
0
34
350
0.96
0.03
3.1
3.4
7.80
4.49
mg/mmol
0.53
23
205
104
1043
0.97
0.00
33.2
14.0
79.17
70.18
umol/l
0.85
104
1043
45
455
0.98
0.00
1.9
2.0
94.47
101.40
pmol/l
0.30
23
200
0
7
0.00
0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
11.42
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
8.24
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
4.54
—
0
8
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: C3_VAGINA_WIDE – Malignant neoplasm of vagina, including Hilmo
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).